Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up

Journal of Clinical Oncology

Volumn 25, Issue 18, 2007, Pages 2554-2559

  Rohatiner, Ama Z S ^a   Nadler, Lee ^a   Davies, Andrew J ^a   Apostolidis, John ^a   Neuberg, Donna ^a   Matthews, Janet ^a   Gribben, John G ^a   Mauch, Peter M ^a   Lister, T Andrew ^a   Freedman, Arnold S ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; MYELODYSPLASIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 34447258197     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.8327     Document Type: Article

References (40)

1. Gall EA, Mallory TB: Malignant lymphoma: A clinicopathological survey of 618 cases. Am J Pathol 18:381-415, 1942
2. Rosenberg SA, Diamond HD, Craver LF: Lymphosarcoma: Survival and the effects of therapy. Am J Roentgenol Radium Ther Nucl Med 85:521-532, 1961
3. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
4. Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282-1290, 1996
5. Reddy S, Saxema V, Pelllettiere E: Stage I and II non-Hodgkin's lymphomas: Long-term results of radiation therapy. Int J Radiat Oncol Biol Phys 16: 687-692, 1989
6. Richards MA, Gregory WM, Hall PA, et al: Management of localized non-Hodgkin's lymphoma: The experience at St. Bartholomew's Hospital 1972-1985. Hematol Oncol 7:1-18, 1989
7. Ezdinli EZ, Anderson JR, Melvin F, et al: Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 3:769-775, 1985
8. Lister TA, Cullen MH, Beard ME, et al: Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. BMJ 1:533-537, 1978
9. Hoppe RT, Kushlan P, Kaplan HS, et al: The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: A preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 58:592-598, 1981
10. Portlock CS, Rosenberg SA, Glatstein E, et al: Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: Preliminary results of a prospective trial. Blood 47:747-756, 1976
11. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
12. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987
13. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
14. Petersen FB, Appelbaum FR, Hill R, et al: Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle. J Clin Oncol 8:638-647, 1990
15. Freedman AS, Ritz J, Neuberg D, et al: Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 77:2524-2529, 1991
16. Brice P, Simon D, Bouabdallah R, et al: High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 11:1585-1590, 2000
17. Rohatiner AZ, Johnson PW, Price CG, et al: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12:1177-1184, 1994
18. Bastion Y, Brice P, Haioun C, et al: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86:3257-3262, 1995
19. Bierman PJ, Vose JM, Anderson JR, et al: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997
20. Nadler LM, Takvorian T, Botnick L, et al: Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet 2:427-431, 1984
21. Apostolidis J, Gupta RK, Grenzelias D, et al: High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up. J Clin Oncol 18:527-536, 2000
22. Darrington DL, Vose JM, Anderson JR, et al: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527-2534, 1994
23. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al: Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT - EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 106:1020-1026, 1999
24. Friedberg JW, Neuberg D, Stone RM, et al: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 17: 3128-3135, 1999
25. Lenz G, Dreyling M, Schiegnitz E, et al: Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 22:4926-4933, 2004
26. Micallef IN, Lillington DM, Apostolidis J, et al: Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18:947-955, 2000
27. Metayer C, Curtis RE, Vose J, et al: Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case-control study. Blood 101:2015-2023, 2003
28. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
29. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
30. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004
31. Rohatiner AZ, Freedman A, Nadler L, et al: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol 5:143-146, 1994 (suppl 2)
32. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
33. Schouten HC, Qian W, Kvaloy S, et al: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 21:3918-3927, 2003
34. Deconinck E, Foussard C, Milpied N, et al: High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS. Blood 105:3817-3823, 2005
35. Lenz G, Dreyling M, Schiegnitz E, et al: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667-2674, 2004
36. Sebban C, Mounier N, Brousse N, et al: Standard chemotherapy with interferon compared to CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the GELA. Blood 108:2540-2544, 2006
37. Brown JR, Yeckes H, Friedberg JW, et al: Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 23:2208-2214, 2005
38. Montoto S, Rohatiner AZ, Canals C, et al: Long-term follow-up of high-dose treatment (HDT) with autologous haematopoietic progenitor cell support in 702 patients (pts.) with follicular lymphoma (FL): An EBMT registry study. J Clin Oncol 24:428s, 2006 (abstr 7526)
39. van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006
40. Forstpointner R, Unterhalt M, Dreyling M, et al: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108: 4003-4008, 2006